Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Oncopeptides in connection with its rights issue (2)
Mandate

Vinge has advised Oncopeptides in connection with its rights issue

March 03, 2026 Capital Markets and Public M&A

Vinge has advised Oncopeptides AB (publ) in connection with a partially guaranteed rights issue which is expected to provide Oncopeptides with proceeds of approximately SEK 200 million before deduction of transaction costs.

Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.

Vinge’s team consisted of Dain Hård Nevonen, Joel Magnusson, Amanda Sandström and Johannes Ekbom.

Related

Vinge advises Revivo Group on the acquisition of Solidenergy

 Revivo Group, a portfolio company of Helix Kapital, has acquired Solidenergy, a leading provider of surface treatment services in the Norwegian market. The company operates within the energy, offshore and infrastructure sectors and is headquartered in Ågotnes outside Bergen. Solidenergy employs approximately 600 people.
March 03, 2026

Vinge advises on the sale of Poseidon Diving Group

 Vinge has advised the sellers in connection with the sale of Poseidon Diving Group AB to Argo Defence Group AB. Poseidon was founded in 1958 and is a leading manufacturer of advanced diving and breathing equipment.
March 02, 2026

Vinge has advised management of atNorth in connection with the sale of atNorth to CPP Investments and Equinix

 Vinge has advised management of atNorth on the sale of atNorth to Canada Pension Plan Investment Board (CPP Investments) and Equinix (EMEA) Management, Inc. from Partners Group and the minority shareholders.
March 02, 2026